格隆汇9月30日丨恒瑞医药(01276.HK)发布公告，2025年9月30日耗资人民币69.45万元回购1万股A股， 回购价格每股69.45-69.45元。 ...

智通财经APP讯，恒瑞医药(01276)发布公告，该公司于2025年9月30日斥资69.45万元人民币回购1万股A 股，每股回购价格为69.45元人民币。 ...

公司名稱： 江蘇恒瑞醫藥股份有限公司 呈交日期： 2025年9月30日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 (註7) (i) 上市發行人已收取其在是次股份發行或庫存股份出售或轉讓應得的全部款項； (viii) 有關債券、借貸股份、票據或公司債券的信託契約/平邊契據經已製備及簽署，有關詳情已送呈公司註冊處處長存檔（如法律如此規定）。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 A | | 於香港聯交所上市 | 否 | | | 證券代號 (如上市) | 600276 | 說明 | A股（於上海證券交易所上市） | ...

Core Insights - The article highlights the top and bottom AH share premium rates as of September 30, with Northeast Electric (00042) leading at 831.03% and Ningde Times (03750) at -15.74% [1][2] Group 1: Top AH Share Premium Rates - Northeast Electric (00042) has a premium rate of 831.03% with a deviation value of 23.88% [2] - Andeli Juice (02218) follows with a premium rate of 225.72% and a deviation value of -4.44% [2] - Zhejiang Shibao (01057) ranks third with a premium rate of 224.28% and a deviation value of 19.52% [2] Group 2: Bottom AH Share Premium Rates - Ningde Times (03750) has the lowest premium rate at -15.74% with a deviation value of -2.42% [2] - Heng Rui Medicine (01276) shows a premium rate of -3.49% and a deviation value of -2.73% [2] - China Merchants Bank (03968) has a premium rate of 3.79% with a deviation value of -2.91% [2] Group 3: Top Deviation Values - Changfei Optical Fiber (06869) leads with a deviation value of 46.77% and a premium rate of 161.18% [2] - Jihong Co., Ltd. (02603) has a deviation value of 28.09% with a premium rate of 47.76% [2] - Dazhong Public Utilities (01635) ranks third with a deviation value of 24.46% and a premium rate of 128.80% [2] Group 4: Bottom Deviation Values - Longyuan Power (00916) has the lowest deviation value at -26.30% with a premium rate of 152.23% [4] - Qin Port Co., Ltd. (03369) follows with a deviation value of -25.11% and a premium rate of 44.48% [4] - Hongye Futures (03678) shows a deviation value of -20.92% with a premium rate of 215.48% [4]

Core Viewpoint - Heng Rui Medicine (01276) experienced a significant stock price increase, with a rise of over 4% at the close, and a current price of HKD 87.95, with a trading volume of HKD 217 million [1] Group 1: Clinical Trials and Approvals - Heng Rui Medicine announced the approval to conduct clinical trials for SHR-7787 injection, SHR-4849 injection, Bevacizumab injection, and Atezolizumab injection [1] Group 2: Licensing Agreement - The company granted Glenmark, an Indian pharmaceutical company, exclusive rights to develop and commercialize its HER2 antibody-drug conjugate, Trastuzumab deruxtecan, in global non-core markets, receiving an upfront payment of USD 18 million and potential milestone payments exceeding USD 1 billion [1] Group 3: Market Rights and Financial Impact - Nomura's report indicates that Heng Rui retains development and commercialization rights for Trastuzumab deruxtecan in major pharmaceutical markets including Greater China, the US, Canada, Europe, and Japan, suggesting that the upfront payment will have a minimal financial impact, but the overall milestone payment scale could be substantial [1] - The collaboration with Glenmark is expected to help unlock the commercial potential of the product, and retaining rights in key markets provides opportunities for larger-scale partnerships in the future [1]

Core Insights - The article highlights significant changes in the stock holdings of various companies under the Hong Kong Stock Connect program, indicating shifts in investor sentiment and potential investment opportunities. Group 1: Stock Increases - Canggang Railway (02169) saw the largest increase in stock holdings, rising by 10.72% to a total holding of 33.06% [1][2] - Goldwind Technology (02208) experienced a 1.17% increase, bringing its holding to 48.64% [1][2] - Zhongchu Innovation (03931) had a 1.02% increase, resulting in a holding of 14.69% [1][2] - The top three companies with the highest increases over the last five trading days were Dazhong Public Utilities (01635) with a 26.45% increase, Canggang Railway (02169) with a 21.07% increase, and Shankao Holdings (00412) with a 12.67% increase [1][3] Group 2: Stock Decreases - Shandong Molong (00568) recorded the largest decrease in stock holdings, dropping by 1.69% to 55.70% [1][2] - Jinli Permanent Magnet (06680) saw a decrease of 1.65%, resulting in a holding of 22.36% [1][2] - Yihua Tong (02402) experienced a 0.89% decrease, bringing its holding to 19.98% [1][2] - Over the last five trading days, the largest decreases were noted for Dongfang Electric (01072) with a 5.93% decrease, Yihua Tong (02402) with a 4.16% decrease, and Ocean Park (02255) with a 2.54% decrease [1][3] Group 3: Long-term Trends - Over the past 20 days, Dazhong Public Utilities (01635) had the highest increase of 27.37%, reaching a holding of 60.02% [4] - Canggang Railway (02169) also saw a significant increase of 21.39%, maintaining a holding of 33.06% [4] - Longfei Optical Fiber and Cable (06869) increased by 17.15%, achieving a holding of 71.17% [4]

Major Events - Lai Kai Pharmaceutical-B (02105) reported positive preliminary results from Phase I clinical MAD study, with LAE102 showing encouraging trends in muscle gain and fat loss [1] - Fuhong Hanlin (02696) received FDA approval for the Phase I clinical trial application of HLX13 for first-line treatment of unresectable hepatocellular carcinoma (HCC) patients [1] - Ningmeng Media (09857) has commenced filming the urban medical emotional drama "Asking Heart 2" [1] - CRRC Corporation (01766) and its subsidiaries signed significant contracts totaling approximately 54.34 billion [1] - Heng Rui Pharmaceutical (01276) received approval to conduct clinical trials for SHR-7787 injection, SHR-4849 injection, Bevacizumab injection, and Atezolizumab injection [1] - Hema Medical (03309) entered into a tripartite global licensing and collaboration agreement with Gilead and Hanmi regarding enecuidar [1] - Jinfang Pharmaceutical-B (02595) completed the enrollment of the first patient in the Phase I/II clinical trial of the molecular glue Pan RAS(ON) inhibitor GFH276 for RAS mutant cancer patients [1] - Gao Shi Medical (02407) obtained international certification for its medical device quality management system [1] Operating Performance - Shenzhen Expressway Company (00548) reported toll revenue of 114 million for the Outer Ring project in August [1] - China National Automobile (00026) announced an annual performance with a post-tax loss attributable to shareholders of 185 million HKD, a year-on-year reduction of 29.64% [1] - OKURA HOLDINGS (01655) reported an annual profit attributable to shareholders of 1.342 billion JPY, a year-on-year decrease of 34.34% [1] - Elephant Future Group (02309) disclosed an annual performance with a loss attributable to owners of approximately 314 million HKD, a year-on-year increase of 71.77% [1] - Henghe Group (00513) reported an annual performance with a loss attributable to owners of approximately 259 million HKD, a year-on-year increase of 0.7% [1]

Core Insights - 恒瑞医药's subsidiaries have received approval from the National Medical Products Administration for clinical trials of four injectable drugs, including SHR-7787, SHR-4849, Bevacizumab, and Adebali monoclonal antibody [1][2] Group 1: SHR-7787 and SHR-4849 - SHR-7787 is a first-class therapeutic biological product that activates T cells to target and kill tumor cells, with no similar drugs approved in China to date. The total R&D investment for SHR-7787 is approximately 48.93 million yuan [1] - SHR-4849 is an antibody-drug conjugate targeting DLL3, designed to treat advanced malignant solid tumors, with no similar drugs approved in China or abroad. The total R&D investment for SHR-4849 is approximately 69.67 million yuan [1] Group 2: Bevacizumab and Adebali Monoclonal Antibody - Bevacizumab, a humanized anti-VEGF monoclonal antibody, was approved in the U.S. in 2004 and has generated global sales of approximately 5.655 billion USD in 2024. The total R&D investment for Bevacizumab by the company is approximately 348.89 million yuan [2] - Adebali monoclonal antibody is a humanized anti-PD-L1 monoclonal antibody approved in February 2023 for first-line treatment of extensive-stage small cell lung cancer. The total R&D investment for Adebali is approximately 939.08 million yuan, with similar products generating combined global sales of approximately 9.648 billion USD in 2024 [2]

Core Viewpoint - Recently, Jiangsu Hengrui Medicine Co., Ltd. announced that its subsidiaries have received approval from the National Medical Products Administration for clinical trials of several injection drugs, indicating progress in their oncology drug development pipeline [1]. Group 1: Clinical Trial Approvals - Hengrui Medicine's subsidiaries, including Suzhou Sediya Biopharmaceutical Co., Ltd., Shanghai Hengrui Medicine Co., Ltd., and Shanghai Shengdi Medicine Co., Ltd., have received clinical trial approval notices for SHR-7787 injection, SHR-4849 injection, Bevacizumab injection, and Atezolizumab injection [1]. - The approved drugs will undergo clinical trials, with SHR-7787 injection being tested in a multicenter, open-label Phase II study in patients with malignant solid tumors [1]. Group 2: Regulatory Compliance - The approved drugs were reviewed and found to meet the requirements for drug registration as per the Drug Administration Law of the People's Republic of China, allowing for the commencement of clinical trials [1]. - The approval date for the drugs was noted as July 17, 2025, indicating a timeline for the regulatory process [1].

HRS-2129 片拟用于治疗急慢性疼痛。经查询，目前国内尚无同靶点药物获批上市。截至目前，HRS- 2129片相关项目累计研发投入约为1.12亿元。 智通财经APP讯，恒瑞医药(01276)发布公告，近日，公司子公司山东盛迪医药有限公司、上海恒瑞医药 有限公司收到国家药品监督管理局(以下简称"国家药监局")核准签发关于HRS-2129片的《药物临床试验 批准通知书》，将于近期开展临床试验。 ...